Several agonists targeting TLR7 and TLR8 have been created.

Merck & Co. extended its vaccine research collaboration with Idera Pharmaceuticals for an additional year. The original agreement, inked in December 2006, focused on research, development, and commercialization of vaccine products containing Idera’s investigational agonist compounds targeting toll-like receptors (TLR) 7, 8, and 9 in the fields of oncology, infectious diseases, and Alzheimer’s disease. For two years, the companies have generated agonists targeting TLR7 and TLR8 incorporating both Merck and Idera chemistry for use in the licensed fields.

“Our two-year research collaboration with Merck scientists has been very productive and has created several novel agonists of TLR7 and TLR8 for potential use in vaccine products,” said Sudhir Agrawal, D.Phil., CEO and CSO, Idera Pharmaceuticals.

Previous articleAurigene to Assist with Advancement of Debiopharm’s Oncology Compound
Next articleNational Neurovision Research Institute to Fund Evaluation of Resolvyx Pharmaceuticals’ Eye Disease Therapeutics